Lv1
36 积分 2025-07-09 加入
The evolution of nerve growth factor inhibition in clinical medicine
2天前
已完结
Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial
13天前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
13天前
已完结
Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial
14天前
已完结
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
14天前
已完结
Mechanisms of Disease: Inflammatory Bowel Diseases
20天前
已完结
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD
28天前
已完结
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
1个月前
已完结
Migraine: epidemiology and systems of care
4个月前
已完结
Urticaria
4个月前
已完结
皖公网安备34019202002308
